Role of antiangiogenic agents in the treatment of metastatic colorectal cancer
This review covers the latest data on antiangiogenic agents used in patients with colorectal cancer. In this article, we describe drugs that have already been included into therapy regimens for colorectal cancer and vascular endothelial growth factor (VEGF) inhibitors that have been approved for oth...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
M. V. Zabelin [verfasserIn] S. S. Gordeev [verfasserIn] L. O. Petrov [verfasserIn] A. A. Kostin [verfasserIn] S. E. Varlamova [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Russisch |
| Erschienen: |
2018 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
In: Тазовая хирургия и онкология - “ABV-press” Publishing house”, LLC, 2021, 8(2018), 1, Seite 11-18 |
|---|---|
| Übergeordnetes Werk: |
volume:8 ; year:2018 ; number:1 ; pages:11-18 |
| Links: |
|---|
| DOI / URN: |
10.17650/2220-3478-2018-8-1-11-18 |
|---|
| Katalog-ID: |
DOAJ027932443 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ027932443 | ||
| 003 | DE-627 | ||
| 005 | 20230307122007.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230226s2018 xx |||||o 00| ||rus c | ||
| 024 | 7 | |a 10.17650/2220-3478-2018-8-1-11-18 |2 doi | |
| 035 | |a (DE-627)DOAJ027932443 | ||
| 035 | |a (DE-599)DOAJ0ba9be16c73040e2bbaad0cd0224040b | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a rus | ||
| 050 | 0 | |a RC254-282 | |
| 100 | 0 | |a M. V. Zabelin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Role of antiangiogenic agents in the treatment of metastatic colorectal cancer |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a This review covers the latest data on antiangiogenic agents used in patients with colorectal cancer. In this article, we describe drugs that have already been included into therapy regimens for colorectal cancer and vascular endothelial growth factor (VEGF) inhibitors that have been approved for other indications. Targeted drugs with a similar mechanism of action that are currently in clinical trials are discussed separately. VEGF-inhibitors are one of the main groups of targeted drugs for colorectal cancer with an acceptable toxicity profile, which can be used both in combination with chemotherapeutic agents and as maintenance treatment. Moreover, these drugs are not dependent on mutational status, which is a significant advantage. | ||
| 650 | 4 | |a colorectal cancer | |
| 650 | 4 | |a rectal cancer | |
| 650 | 4 | |a targeted therapy | |
| 650 | 4 | |a vegf inhibitors | |
| 653 | 0 | |a Neoplasms. Tumors. Oncology. Including cancer and carcinogens | |
| 700 | 0 | |a S. S. Gordeev |e verfasserin |4 aut | |
| 700 | 0 | |a L. O. Petrov |e verfasserin |4 aut | |
| 700 | 0 | |a A. A. Kostin |e verfasserin |4 aut | |
| 700 | 0 | |a S. E. Varlamova |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Тазовая хирургия и онкология |d “ABV-press” Publishing house”, LLC, 2021 |g 8(2018), 1, Seite 11-18 |w (DE-627)176063123X |x 26869594 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2018 |g number:1 |g pages:11-18 |
| 856 | 4 | 0 | |u https://doi.org/10.17650/2220-3478-2018-8-1-11-18 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/0ba9be16c73040e2bbaad0cd0224040b |z kostenfrei |
| 856 | 4 | 0 | |u https://ok.abvpress.ru/jour/article/view/238 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2686-9594 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2018 |e 1 |h 11-18 | ||
| author_variant |
m v z mvz s s g ssg l o p lop a a k aak s e v sev |
|---|---|
| matchkey_str |
article:26869594:2018----::oefninigncgnsnhtetetfeatt |
| hierarchy_sort_str |
2018 |
| callnumber-subject-code |
RC |
| publishDate |
2018 |
| allfields |
10.17650/2220-3478-2018-8-1-11-18 doi (DE-627)DOAJ027932443 (DE-599)DOAJ0ba9be16c73040e2bbaad0cd0224040b DE-627 ger DE-627 rakwb rus RC254-282 M. V. Zabelin verfasserin aut Role of antiangiogenic agents in the treatment of metastatic colorectal cancer 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier This review covers the latest data on antiangiogenic agents used in patients with colorectal cancer. In this article, we describe drugs that have already been included into therapy regimens for colorectal cancer and vascular endothelial growth factor (VEGF) inhibitors that have been approved for other indications. Targeted drugs with a similar mechanism of action that are currently in clinical trials are discussed separately. VEGF-inhibitors are one of the main groups of targeted drugs for colorectal cancer with an acceptable toxicity profile, which can be used both in combination with chemotherapeutic agents and as maintenance treatment. Moreover, these drugs are not dependent on mutational status, which is a significant advantage. colorectal cancer rectal cancer targeted therapy vegf inhibitors Neoplasms. Tumors. Oncology. Including cancer and carcinogens S. S. Gordeev verfasserin aut L. O. Petrov verfasserin aut A. A. Kostin verfasserin aut S. E. Varlamova verfasserin aut In Тазовая хирургия и онкология “ABV-press” Publishing house”, LLC, 2021 8(2018), 1, Seite 11-18 (DE-627)176063123X 26869594 nnns volume:8 year:2018 number:1 pages:11-18 https://doi.org/10.17650/2220-3478-2018-8-1-11-18 kostenfrei https://doaj.org/article/0ba9be16c73040e2bbaad0cd0224040b kostenfrei https://ok.abvpress.ru/jour/article/view/238 kostenfrei https://doaj.org/toc/2686-9594 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 8 2018 1 11-18 |
| spelling |
10.17650/2220-3478-2018-8-1-11-18 doi (DE-627)DOAJ027932443 (DE-599)DOAJ0ba9be16c73040e2bbaad0cd0224040b DE-627 ger DE-627 rakwb rus RC254-282 M. V. Zabelin verfasserin aut Role of antiangiogenic agents in the treatment of metastatic colorectal cancer 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier This review covers the latest data on antiangiogenic agents used in patients with colorectal cancer. In this article, we describe drugs that have already been included into therapy regimens for colorectal cancer and vascular endothelial growth factor (VEGF) inhibitors that have been approved for other indications. Targeted drugs with a similar mechanism of action that are currently in clinical trials are discussed separately. VEGF-inhibitors are one of the main groups of targeted drugs for colorectal cancer with an acceptable toxicity profile, which can be used both in combination with chemotherapeutic agents and as maintenance treatment. Moreover, these drugs are not dependent on mutational status, which is a significant advantage. colorectal cancer rectal cancer targeted therapy vegf inhibitors Neoplasms. Tumors. Oncology. Including cancer and carcinogens S. S. Gordeev verfasserin aut L. O. Petrov verfasserin aut A. A. Kostin verfasserin aut S. E. Varlamova verfasserin aut In Тазовая хирургия и онкология “ABV-press” Publishing house”, LLC, 2021 8(2018), 1, Seite 11-18 (DE-627)176063123X 26869594 nnns volume:8 year:2018 number:1 pages:11-18 https://doi.org/10.17650/2220-3478-2018-8-1-11-18 kostenfrei https://doaj.org/article/0ba9be16c73040e2bbaad0cd0224040b kostenfrei https://ok.abvpress.ru/jour/article/view/238 kostenfrei https://doaj.org/toc/2686-9594 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 8 2018 1 11-18 |
| allfields_unstemmed |
10.17650/2220-3478-2018-8-1-11-18 doi (DE-627)DOAJ027932443 (DE-599)DOAJ0ba9be16c73040e2bbaad0cd0224040b DE-627 ger DE-627 rakwb rus RC254-282 M. V. Zabelin verfasserin aut Role of antiangiogenic agents in the treatment of metastatic colorectal cancer 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier This review covers the latest data on antiangiogenic agents used in patients with colorectal cancer. In this article, we describe drugs that have already been included into therapy regimens for colorectal cancer and vascular endothelial growth factor (VEGF) inhibitors that have been approved for other indications. Targeted drugs with a similar mechanism of action that are currently in clinical trials are discussed separately. VEGF-inhibitors are one of the main groups of targeted drugs for colorectal cancer with an acceptable toxicity profile, which can be used both in combination with chemotherapeutic agents and as maintenance treatment. Moreover, these drugs are not dependent on mutational status, which is a significant advantage. colorectal cancer rectal cancer targeted therapy vegf inhibitors Neoplasms. Tumors. Oncology. Including cancer and carcinogens S. S. Gordeev verfasserin aut L. O. Petrov verfasserin aut A. A. Kostin verfasserin aut S. E. Varlamova verfasserin aut In Тазовая хирургия и онкология “ABV-press” Publishing house”, LLC, 2021 8(2018), 1, Seite 11-18 (DE-627)176063123X 26869594 nnns volume:8 year:2018 number:1 pages:11-18 https://doi.org/10.17650/2220-3478-2018-8-1-11-18 kostenfrei https://doaj.org/article/0ba9be16c73040e2bbaad0cd0224040b kostenfrei https://ok.abvpress.ru/jour/article/view/238 kostenfrei https://doaj.org/toc/2686-9594 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 8 2018 1 11-18 |
| allfieldsGer |
10.17650/2220-3478-2018-8-1-11-18 doi (DE-627)DOAJ027932443 (DE-599)DOAJ0ba9be16c73040e2bbaad0cd0224040b DE-627 ger DE-627 rakwb rus RC254-282 M. V. Zabelin verfasserin aut Role of antiangiogenic agents in the treatment of metastatic colorectal cancer 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier This review covers the latest data on antiangiogenic agents used in patients with colorectal cancer. In this article, we describe drugs that have already been included into therapy regimens for colorectal cancer and vascular endothelial growth factor (VEGF) inhibitors that have been approved for other indications. Targeted drugs with a similar mechanism of action that are currently in clinical trials are discussed separately. VEGF-inhibitors are one of the main groups of targeted drugs for colorectal cancer with an acceptable toxicity profile, which can be used both in combination with chemotherapeutic agents and as maintenance treatment. Moreover, these drugs are not dependent on mutational status, which is a significant advantage. colorectal cancer rectal cancer targeted therapy vegf inhibitors Neoplasms. Tumors. Oncology. Including cancer and carcinogens S. S. Gordeev verfasserin aut L. O. Petrov verfasserin aut A. A. Kostin verfasserin aut S. E. Varlamova verfasserin aut In Тазовая хирургия и онкология “ABV-press” Publishing house”, LLC, 2021 8(2018), 1, Seite 11-18 (DE-627)176063123X 26869594 nnns volume:8 year:2018 number:1 pages:11-18 https://doi.org/10.17650/2220-3478-2018-8-1-11-18 kostenfrei https://doaj.org/article/0ba9be16c73040e2bbaad0cd0224040b kostenfrei https://ok.abvpress.ru/jour/article/view/238 kostenfrei https://doaj.org/toc/2686-9594 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 8 2018 1 11-18 |
| allfieldsSound |
10.17650/2220-3478-2018-8-1-11-18 doi (DE-627)DOAJ027932443 (DE-599)DOAJ0ba9be16c73040e2bbaad0cd0224040b DE-627 ger DE-627 rakwb rus RC254-282 M. V. Zabelin verfasserin aut Role of antiangiogenic agents in the treatment of metastatic colorectal cancer 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier This review covers the latest data on antiangiogenic agents used in patients with colorectal cancer. In this article, we describe drugs that have already been included into therapy regimens for colorectal cancer and vascular endothelial growth factor (VEGF) inhibitors that have been approved for other indications. Targeted drugs with a similar mechanism of action that are currently in clinical trials are discussed separately. VEGF-inhibitors are one of the main groups of targeted drugs for colorectal cancer with an acceptable toxicity profile, which can be used both in combination with chemotherapeutic agents and as maintenance treatment. Moreover, these drugs are not dependent on mutational status, which is a significant advantage. colorectal cancer rectal cancer targeted therapy vegf inhibitors Neoplasms. Tumors. Oncology. Including cancer and carcinogens S. S. Gordeev verfasserin aut L. O. Petrov verfasserin aut A. A. Kostin verfasserin aut S. E. Varlamova verfasserin aut In Тазовая хирургия и онкология “ABV-press” Publishing house”, LLC, 2021 8(2018), 1, Seite 11-18 (DE-627)176063123X 26869594 nnns volume:8 year:2018 number:1 pages:11-18 https://doi.org/10.17650/2220-3478-2018-8-1-11-18 kostenfrei https://doaj.org/article/0ba9be16c73040e2bbaad0cd0224040b kostenfrei https://ok.abvpress.ru/jour/article/view/238 kostenfrei https://doaj.org/toc/2686-9594 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 8 2018 1 11-18 |
| language |
Russian |
| source |
In Тазовая хирургия и онкология 8(2018), 1, Seite 11-18 volume:8 year:2018 number:1 pages:11-18 |
| sourceStr |
In Тазовая хирургия и онкология 8(2018), 1, Seite 11-18 volume:8 year:2018 number:1 pages:11-18 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
colorectal cancer rectal cancer targeted therapy vegf inhibitors Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| isfreeaccess_bool |
true |
| container_title |
Тазовая хирургия и онкология |
| authorswithroles_txt_mv |
M. V. Zabelin @@aut@@ S. S. Gordeev @@aut@@ L. O. Petrov @@aut@@ A. A. Kostin @@aut@@ S. E. Varlamova @@aut@@ |
| publishDateDaySort_date |
2018-01-01T00:00:00Z |
| hierarchy_top_id |
176063123X |
| id |
DOAJ027932443 |
| language_de |
russisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ027932443</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230307122007.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230226s2018 xx |||||o 00| ||rus c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.17650/2220-3478-2018-8-1-11-18</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ027932443</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ0ba9be16c73040e2bbaad0cd0224040b</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">rus</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC254-282</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">M. V. Zabelin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Role of antiangiogenic agents in the treatment of metastatic colorectal cancer</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2018</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">This review covers the latest data on antiangiogenic agents used in patients with colorectal cancer. In this article, we describe drugs that have already been included into therapy regimens for colorectal cancer and vascular endothelial growth factor (VEGF) inhibitors that have been approved for other indications. Targeted drugs with a similar mechanism of action that are currently in clinical trials are discussed separately. VEGF-inhibitors are one of the main groups of targeted drugs for colorectal cancer with an acceptable toxicity profile, which can be used both in combination with chemotherapeutic agents and as maintenance treatment. Moreover, these drugs are not dependent on mutational status, which is a significant advantage.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">colorectal cancer</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">rectal cancer</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">targeted therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">vegf inhibitors</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Neoplasms. Tumors. Oncology. Including cancer and carcinogens</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">S. S. Gordeev</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">L. O. Petrov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">A. A. Kostin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">S. E. Varlamova</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Тазовая хирургия и онкология</subfield><subfield code="d">“ABV-press” Publishing house”, LLC, 2021</subfield><subfield code="g">8(2018), 1, Seite 11-18</subfield><subfield code="w">(DE-627)176063123X</subfield><subfield code="x">26869594</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:8</subfield><subfield code="g">year:2018</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:11-18</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.17650/2220-3478-2018-8-1-11-18</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/0ba9be16c73040e2bbaad0cd0224040b</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://ok.abvpress.ru/jour/article/view/238</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2686-9594</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">8</subfield><subfield code="j">2018</subfield><subfield code="e">1</subfield><subfield code="h">11-18</subfield></datafield></record></collection>
|
| callnumber-first |
R - Medicine |
| author |
M. V. Zabelin |
| spellingShingle |
M. V. Zabelin misc RC254-282 misc colorectal cancer misc rectal cancer misc targeted therapy misc vegf inhibitors misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens Role of antiangiogenic agents in the treatment of metastatic colorectal cancer |
| authorStr |
M. V. Zabelin |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)176063123X |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut aut |
| collection |
DOAJ |
| remote_str |
true |
| callnumber-label |
RC254-282 |
| illustrated |
Not Illustrated |
| issn |
26869594 |
| topic_title |
RC254-282 Role of antiangiogenic agents in the treatment of metastatic colorectal cancer colorectal cancer rectal cancer targeted therapy vegf inhibitors |
| topic |
misc RC254-282 misc colorectal cancer misc rectal cancer misc targeted therapy misc vegf inhibitors misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| topic_unstemmed |
misc RC254-282 misc colorectal cancer misc rectal cancer misc targeted therapy misc vegf inhibitors misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| topic_browse |
misc RC254-282 misc colorectal cancer misc rectal cancer misc targeted therapy misc vegf inhibitors misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Тазовая хирургия и онкология |
| hierarchy_parent_id |
176063123X |
| hierarchy_top_title |
Тазовая хирургия и онкология |
| isfreeaccess_txt |
true |
| familylinks_str_mv |
(DE-627)176063123X |
| title |
Role of antiangiogenic agents in the treatment of metastatic colorectal cancer |
| ctrlnum |
(DE-627)DOAJ027932443 (DE-599)DOAJ0ba9be16c73040e2bbaad0cd0224040b |
| title_full |
Role of antiangiogenic agents in the treatment of metastatic colorectal cancer |
| author_sort |
M. V. Zabelin |
| journal |
Тазовая хирургия и онкология |
| journalStr |
Тазовая хирургия и онкология |
| callnumber-first-code |
R |
| lang_code |
rus |
| isOA_bool |
true |
| recordtype |
marc |
| publishDateSort |
2018 |
| contenttype_str_mv |
txt |
| container_start_page |
11 |
| author_browse |
M. V. Zabelin S. S. Gordeev L. O. Petrov A. A. Kostin S. E. Varlamova |
| container_volume |
8 |
| class |
RC254-282 |
| format_se |
Elektronische Aufsätze |
| author-letter |
M. V. Zabelin |
| doi_str_mv |
10.17650/2220-3478-2018-8-1-11-18 |
| author2-role |
verfasserin |
| title_sort |
role of antiangiogenic agents in the treatment of metastatic colorectal cancer |
| callnumber |
RC254-282 |
| title_auth |
Role of antiangiogenic agents in the treatment of metastatic colorectal cancer |
| abstract |
This review covers the latest data on antiangiogenic agents used in patients with colorectal cancer. In this article, we describe drugs that have already been included into therapy regimens for colorectal cancer and vascular endothelial growth factor (VEGF) inhibitors that have been approved for other indications. Targeted drugs with a similar mechanism of action that are currently in clinical trials are discussed separately. VEGF-inhibitors are one of the main groups of targeted drugs for colorectal cancer with an acceptable toxicity profile, which can be used both in combination with chemotherapeutic agents and as maintenance treatment. Moreover, these drugs are not dependent on mutational status, which is a significant advantage. |
| abstractGer |
This review covers the latest data on antiangiogenic agents used in patients with colorectal cancer. In this article, we describe drugs that have already been included into therapy regimens for colorectal cancer and vascular endothelial growth factor (VEGF) inhibitors that have been approved for other indications. Targeted drugs with a similar mechanism of action that are currently in clinical trials are discussed separately. VEGF-inhibitors are one of the main groups of targeted drugs for colorectal cancer with an acceptable toxicity profile, which can be used both in combination with chemotherapeutic agents and as maintenance treatment. Moreover, these drugs are not dependent on mutational status, which is a significant advantage. |
| abstract_unstemmed |
This review covers the latest data on antiangiogenic agents used in patients with colorectal cancer. In this article, we describe drugs that have already been included into therapy regimens for colorectal cancer and vascular endothelial growth factor (VEGF) inhibitors that have been approved for other indications. Targeted drugs with a similar mechanism of action that are currently in clinical trials are discussed separately. VEGF-inhibitors are one of the main groups of targeted drugs for colorectal cancer with an acceptable toxicity profile, which can be used both in combination with chemotherapeutic agents and as maintenance treatment. Moreover, these drugs are not dependent on mutational status, which is a significant advantage. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ |
| container_issue |
1 |
| title_short |
Role of antiangiogenic agents in the treatment of metastatic colorectal cancer |
| url |
https://doi.org/10.17650/2220-3478-2018-8-1-11-18 https://doaj.org/article/0ba9be16c73040e2bbaad0cd0224040b https://ok.abvpress.ru/jour/article/view/238 https://doaj.org/toc/2686-9594 |
| remote_bool |
true |
| author2 |
S. S. Gordeev L. O. Petrov A. A. Kostin S. E. Varlamova |
| author2Str |
S. S. Gordeev L. O. Petrov A. A. Kostin S. E. Varlamova |
| ppnlink |
176063123X |
| callnumber-subject |
RC - Internal Medicine |
| mediatype_str_mv |
c |
| isOA_txt |
true |
| hochschulschrift_bool |
false |
| doi_str |
10.17650/2220-3478-2018-8-1-11-18 |
| callnumber-a |
RC254-282 |
| up_date |
2024-07-03T14:49:34.359Z |
| _version_ |
1803569777195614208 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ027932443</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230307122007.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230226s2018 xx |||||o 00| ||rus c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.17650/2220-3478-2018-8-1-11-18</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ027932443</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ0ba9be16c73040e2bbaad0cd0224040b</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">rus</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC254-282</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">M. V. Zabelin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Role of antiangiogenic agents in the treatment of metastatic colorectal cancer</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2018</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">This review covers the latest data on antiangiogenic agents used in patients with colorectal cancer. In this article, we describe drugs that have already been included into therapy regimens for colorectal cancer and vascular endothelial growth factor (VEGF) inhibitors that have been approved for other indications. Targeted drugs with a similar mechanism of action that are currently in clinical trials are discussed separately. VEGF-inhibitors are one of the main groups of targeted drugs for colorectal cancer with an acceptable toxicity profile, which can be used both in combination with chemotherapeutic agents and as maintenance treatment. Moreover, these drugs are not dependent on mutational status, which is a significant advantage.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">colorectal cancer</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">rectal cancer</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">targeted therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">vegf inhibitors</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Neoplasms. Tumors. Oncology. Including cancer and carcinogens</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">S. S. Gordeev</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">L. O. Petrov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">A. A. Kostin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">S. E. Varlamova</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Тазовая хирургия и онкология</subfield><subfield code="d">“ABV-press” Publishing house”, LLC, 2021</subfield><subfield code="g">8(2018), 1, Seite 11-18</subfield><subfield code="w">(DE-627)176063123X</subfield><subfield code="x">26869594</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:8</subfield><subfield code="g">year:2018</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:11-18</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.17650/2220-3478-2018-8-1-11-18</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/0ba9be16c73040e2bbaad0cd0224040b</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://ok.abvpress.ru/jour/article/view/238</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2686-9594</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">8</subfield><subfield code="j">2018</subfield><subfield code="e">1</subfield><subfield code="h">11-18</subfield></datafield></record></collection>
|
| score |
7.401143 |